Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 1:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 757 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Active then Sham Treatment Clear all
Recruiting Not applicable Interventional

Impact of a Biophoton Therapy on Patients With Brain Disorders

NCT06147999
View directory record Official record
Conditions
Brain Disorders - Alzheimer's Disease, Dementia, Parkinson's Disease, Traumatic Brain Injury
Interventions
Biophotonizer - a Biophoton Generator
Device
Lead sponsor
First Institute of All Medicines
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Butler, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 15, 2026, 1:06 PM EDT
Recruiting Not applicable Interventional

Home Neuromodulation for Neurogenic Bladder Management in Spinal Cord Injury

NCT07264868
View directory record Official record
Conditions
Spinal Cord Injury (SCI), Neurogenic Bladder (NB)
Interventions
iTNS, Sham iTNS
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 15, 2026, 1:06 PM EDT
Enrolling by invitation Phase 4 Interventional Accepts healthy volunteers

Characterizing Transcranial Focused Ultrasound Neuromodulation During Sedation

NCT07161518
View directory record Official record
Conditions
Healthy Participants
Interventions
Low-intensity transcranial ultrasound, Propofol
Device · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 15, 2026, 1:06 PM EDT
Completed Phase 3 Interventional

Treatment of Lead-Exposed Children Trial

NCT00342849
View directory record Official record
Conditions
Lead Exposure
Interventions
Succimer, Placebo
Drug
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
12 Months to 33 Months
Enrollment
780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2015
U.S. locations
4
States / cities
Baltimore, Maryland • Newark, New Jersey • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 15, 2026, 1:06 PM EDT
Completed Not applicable Interventional

Treating Word Finding Difficulties in Traumatic Brain Injury With HD-tDCS

NCT06840808
View directory record Official record
Conditions
Traumatic Brain Injury, Cognitive Change, Word Finding Difficulty, Acquired Brain Injury
Interventions
Active Transcranial direct current stimulation, Sham Transcranial direct current stimulation
Device
Lead sponsor
The University of Texas at Dallas
Other
Eligibility
18 Years to 85 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 15, 2026, 1:06 PM EDT
Terminated Not applicable Interventional Results available

PTNS for Female Patients Suffering From Multiple Sclerosis

NCT05422625
View directory record Official record
Conditions
Multiple Sclerosis, Overactive Bladder
Interventions
PTNS Treatment, Sham PTNS Treatment
Device
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 15, 2026, 1:06 PM EDT
Completed Phase 3 Interventional Results available

Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis

NCT00432835
View directory record Official record
Conditions
Gastroparesis
Interventions
Gastric Electrical Stimulator, Enterra, Medtronics, Inc.
Device
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Oct 15, 2026, 1:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

PACT (Platelet Activity After Clopidogrel Termination)

NCT00619073
View directory record Official record
Conditions
Blood Platelets, Clopidogrel
Interventions
clopidogrel + aspirin, placebo, Aspirin
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
21 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 31, 2018 · Synced Oct 15, 2026, 1:06 PM EDT
Completed Phase 4 Interventional Results available

Nicotine Replacement Therapy (NRT) and Bupropion Mechanisms of Effectiveness in Smokers

NCT01048944
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Bupropion SR, Nicotine Patch, Placebo Patch and Placebo Pill
Drug
Lead sponsor
Southern Illinois University Carbondale
Other
Eligibility
18 Years to 55 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Carbondale, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 25, 2014 · Synced Oct 15, 2026, 1:06 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension

NCT02235909
View directory record Official record
Conditions
Hypertension
Interventions
Azilsartan Medoxomil Low-dose, Losartan, Placebo for Azilsartan Medoxomil, Placebo for Losartan, Azilsartan Medoxomil Medium-dose (20 mg), Azilsartan Medoxomil High-dose (40 mg)
Drug
Lead sponsor
Arbor Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 18 Years
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
17
States / cities
Anaheim, California • Hialeah, Florida • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Oct 15, 2026, 1:06 PM EDT
Completed Phase 4 Interventional Results available

A Pilot Study of Suvorexant for Insomnia in Parkinson Disease

NCT02729714
View directory record Official record
Conditions
Insomnia
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
Burdick, Daniel, M.D.
Individual
Eligibility
30 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 15, 2026, 1:06 PM EDT
Terminated Phase 3 Interventional Results available

Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease

NCT00436748
View directory record Official record
Conditions
Anemia, Chronic Kidney Disease, Kidney Disease
Interventions
Darbepoetin Alfa, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
1 Year to 18 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
42
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Oct 15, 2026, 1:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of PVP001, PVP002, and PVP003 in Healthy Adults and PVP001 and PVP002 in Adults With Celiac Disease

NCT03701555
View directory record Official record
Conditions
Digestive System Disease
Interventions
PvP001 placebo, PvP001 100 mg, PvP001 300 mg, PvP001 900 mg, Maximum Feasible Dose (MFD) of PvP002, Maximum Tolerated Dose (MTD) of PvP001, MTD of PvP001 following 7 days of PPI treatment, PvP002 placebo, PvP001 600 mg, PvP003 placebo, PvP003, PvP003 150 mg
Other · Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
139 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Oct 15, 2026, 1:06 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Bioavailability of EPA and DHA From Two Dietary Supplements

NCT01908374
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
DHA-rich fish oil versus Phospholipid-rich fish oil
Dietary Supplement
Lead sponsor
Arctic Nutrition AS
Industry
Eligibility
18 Years to 59 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 25, 2013 · Synced Oct 15, 2026, 1:06 PM EDT
Recruiting Phase 2 Interventional

A Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)

NCT07409103
View directory record Official record
Conditions
Active Rheumatoid Arthritis
Interventions
ELV001 25 mg, ELV001 75 mg, ELV001 125 mg, Placebo
Drug
Lead sponsor
Elevara Medicines Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
22
States / cities
Gilbert, Arizona • Glendale, Arizona • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 15, 2026, 1:06 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Lebrikizumab in Adolescent Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication

NCT01875003
View directory record Official record
Conditions
Asthma
Interventions
Lebrikizumab, Placebo, Standard of Care
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years to 17 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
16
States / cities
Mission Viejo, California • Stockton, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 15, 2026, 1:06 PM EDT
Completed Phase 4 Interventional Results available

Suvorexant and Trauma Related Insomnia

NCT02704754
View directory record Official record
Conditions
Insomnia, Posttraumatic Stress Disorder
Interventions
suvorexant, placebo
Drug · Other
Lead sponsor
Howard University
Other
Eligibility
18 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 15, 2026, 1:06 PM EDT
Completed Not applicable Interventional Results available

Pulsed Electromagnetic Fields for Post-Amputation Pain

NCT05392803
View directory record Official record
Conditions
Phantom Limb Pain, Residual Limb Pain
Interventions
Active then Sham Treatment, Sham then Active Treatment
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 15, 2026, 1:06 PM EDT
Completed Phase 2 Interventional Results available

Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)

NCT03682770
View directory record Official record
Conditions
Peanut Allergy
Interventions
Dupilumab, Placebo matching dupilumab, AR101
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
6 Years to 17 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
25
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Oct 15, 2026, 1:06 PM EDT
Completed Phase 2 Interventional Results available

Effect of Desipramine on Upper Airway Collapsibility and Genioglossus Muscle Activity in Patients With Obstructive Sleep Apnea - Study B

NCT02436031
View directory record Official record
Conditions
Sleep Apnea, Obstructive
Interventions
Desipramine, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Oct 15, 2026, 1:06 PM EDT
Completed Phase 2 Interventional

Depressed Mood Improvement Through Nicotine Dosing 3

NCT05746273
View directory record Official record
Conditions
Depressive Disorder
Interventions
Transdermal Nicotine Patch, Transdermal Placebo Patch
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
60 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 15, 2026, 1:06 PM EDT
Completed Phase 4 Interventional Results available

Evaluating the Effectiveness of Escitalopram to Prevent Depression in Head and Neck Cancer Patients Receiving Treatment

NCT00536172
View directory record Official record
Conditions
Depression
Interventions
Escitalopram, Placebo
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 15, 2026, 1:06 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits

NCT04419272
View directory record Official record
Conditions
Epilepsy
Interventions
Methylphenidate, Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
4
States / cities
Miami, Florida • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 15, 2026, 1:06 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of QVA149 in COPD Patients

NCT02487446
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
QVA149, Umeclidinium/vilanterol, Placebo (umeclidinium/vilanterol), Placebo (QVA149)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
58
States / cities
Andalusia, Alabama • Anniston, Alabama • Jasper, Alabama + 52 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Oct 15, 2026, 1:06 PM EDT